相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
Jeremy Force et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers
Ibrahim Halil Erdogdu
GASTROENTEROLOGY RESEARCH AND PRACTICE (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
Shin Hye Yoo et al.
SCIENTIFIC REPORTS (2019)
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
Michael Friedrich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study
Wenyu Wu et al.
CANCER MEDICINE (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
Francisco Perea et al.
ONCOTARGET (2018)
Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study
Icro Meattini et al.
CLINICAL BREAST CANCER (2018)
Tumor-infiltrating lymphocytes in androgen receptor-positive, triple-negative breast cancer.
Roberto Antonio Leon-Ferre et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
Erik A. Dill et al.
MODERN PATHOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang et al.
CANCER RESEARCH (2017)
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Michal Smahel
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Targeting immune checkpoints in breast cancer: an update of early results
Cinzia Solinas et al.
ESMO OPEN (2017)
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages An Assessment of 245 Primary and 40 Metastatic Tumors
Erik A. Dill et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers
Anne M. Mills et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Immune Blockade Inhibition in Breast Cancer
Ioannis A. Voutsadakis
ANTICANCER RESEARCH (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
Hiroyuki Inoue et al.
ONCOIMMUNOLOGY (2016)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
Mitsuya Itoh et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
Marco M. Hefti et al.
BREAST CANCER RESEARCH (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Masayuki Inoue et al.
ONCOIMMUNOLOGY (2012)
Clinical implication of HLA class I expression in breast cancer
Koichi Kaneko et al.
BMC CANCER (2011)
Expression regulation of major histocompatibility complex class I and class II encoding genes
Peter J. van den Elsen
FRONTIERS IN IMMUNOLOGY (2011)
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Jacques Neefjes et al.
NATURE REVIEWS IMMUNOLOGY (2011)
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway
F Herrmann et al.
CANCER RESEARCH (2004)
分享论文
